Trial Profile
A Safety Confirmation Study On Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 27 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2010 Planned end date changed from 1 Dec 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
- 15 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.